Press

Core One Labs Prepares for Commercial Production of API-Grade Psilocybin Plans Initial Production Run at GMP Facility in January

Nov 21 • 3 min read

Core One Labs Inc. (CSE: COOL | OTC: CLABF | Frankfurt: LD6, WKN: A3CSSU) is pleased to announce the initial production run of its psilocybin active pharmaceutical ingredient (API) product at a good manufacturing practices (GMP) facility is projected for January 2023, to test the Company’s commercial production capabilities. After a successful commercial production trial, the Company…

Mydecine Innovations Group Files Prospectus Supplement and Announces Closing Under Share Subscription Agreement

Nov 21 • 2 min read

Mydecine Innovations Group Inc. (NEO:MYCO | OTC:MYCOF | FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that, in connection with its previously announced Common Share Subscription Agreement with a third-party investor dated August…

Wellbeing Digital Announces Resignation of Directors

Nov 21 • 2 min read

Wellbeing Digital Sciences Inc. (NEO: MEDI | OTC: KONEF | FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that James Henning and Steven Inglefield have stepped down as directors of the Company “James has served on the…

Wellbeing Subsidiary KGK Science Enters into Research Contract With Nova Mentis for Phase II A Clinical Trial

Nov 21 • 3 min read

Wellbeing Digital Sciences Inc. (NEO: MEDI | OTC: KONEF | FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that its wholly owned subsidiary KGK Science Inc., has entered into a research services agreement with Nova Mentis Life…

Reunion Neuroscience Puts in Place At-The-Market Equity Facility

Nov 21 • 3 min read

Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN), a biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, today announced that it has entered into an equity distribution agreement with Canaccord Genuity to establish an at-the-market equity facility. Pursuant to the at-the-market equity facility (ATM Facility), the Company may, at…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435